An abstract discussing the results of a study performed by researchers at The Johns Hopkins Hospital in Baltimore, USA, has been accepted by the USCAP for presentation at their annual conference in March 2018.
An abstract discussing the results of a study performed by researchers at The Johns Hopkins Hospital in Baltimore, USA, has been accepted by the United States and Canadian Academy of Pathology (USCAP) for presentation at their annual conference in March 2018.
Researchers from Johns Hopkins said the study, which commenced in July 2016, is based on results from a cohort of 500 patients undergoing investigation for bladder cancer by urine cytology and/or cystoscopy. Testing for the presence of hTERT in urothelial cells was performed on all 500 patients, and the results correlated with findings of the other tests.
The USCAP annual conference will be held in Vancouver, Canada from March 17 – 23, 2018. USCAP describes the meeting as the largest and most influential meeting of pathologists in the world. It is attended by over 5,000 pathologists from almost 90 countries.
On the acceptance of the abstract, Sienna CEO Matthew Hoskin said “Having the results of a study on Sienna’s IVD test presented at such a well-attended meeting gives it terrific exposure to a large number of physicians who will have the opportunity to familiarise themselves with the test. Johns Hopkins is a renowned research institution that employs researchers who are at the leading edge of their field. The fact that the results of the study will be presented by such a prestigious institution adds credibility to the findings.”
Johns Hopkins Hospital is the teaching hospital and biomedical research facility of the Johns Hopkins School of Medicine, located in Baltimore, Maryland, USA. The hospital is a non-profit academic medical centre, setting healthcare standards in patient care, research, and education.
